BAVA Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:

  • The Annual Report for 2023 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2024 was also adopted.
  • The Remuneration Report for 2023 was approved.
  • The Board of Directors and the Board of Management were discharged from liability.
  • Luc Debryune, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter and Johan van Hoof were re-elected, and Montse Montaner was elected to the Board of Directors. The Board of Directors constituted itself with Luc Debruyne as Chairman and Anders Gersel Pedersen as Deputy Chairman.
  • KPMG was elected as the Company’s new auditor.
  • The proposal to authorize the Board of Directors to increase the share capital of the Company was adopted.
  • The proposal to authorize the Board of Directors to issue convertible notes which give the right to subscribe for new shares in the Company was adopted.
  • The proposal to authorize the Board of Directors to issue warrants was adopted.
  • The Remuneration Policy was approved.
  • The proposed remuneration of the Board of Directors and the Board Committees for the current financial year was approved.
  • The proposal to authorize the Board of Directors on behalf of the Company to purchase own shares in the Company was adopted.

Minutes and voting results from the Annual General Meeting will be published on the Company’s website within two weeks.

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 07 / 2024

Attachment



EN
16/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines ...

Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU’s capability to respond to future biological threats and emergencies by enabl...

 PRESS RELEASE

Bavarian Nordic Initiates Rolling Submission of Biologics License Appl...

Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older. Bavarian Nordic will submit additional data over the coming months, aiming to complete the ...

 PRESS RELEASE

Indberetning af ledende medarbejdere og disses nærtståendes transaktio...

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer KØBENHAVN, Danmark, 22. april 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. Transaktionen vedrører overdragelse af betingede aktier, der blev tildelt til medlemmer af bestyrelsen i Bavarian Nordic A/S som den del af vederlaget for 2021, og i overensstemmelse med generalforsa...

 PRESS RELEASE

Report of transactions of shares and related securities of Bavarian No...

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transactions concern the vesting of restricted stock units (RSUs) awarded to members of the Board of Directors of Bavarian Nordic A/S as ...

 PRESS RELEASE

Beslutninger på den ordinære generalforsamling 2024 i Bavarian Nordic ...

Beslutninger på den ordinære generalforsamling 2024 i Bavarian Nordic A/S KØBENHAVN, Danmark, 16. april 2024 – Bavarian Nordic A/S (OMX: BAVA) har i dag afholdt ordinær generalforsamling med følgende resultater: Årsrapporten for 2023 blev godkendt. Bestyrelsens forslag om, at overføre årets resultat til 2024 blev ligeledes godkendt.Vederlagsrapporten for 2023 blev godkendt.Generalforsamlingen meddelte bestyrelsen og direktionen decharge.Til bestyrelsen genvalgtes Luc Debruyne, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter og Johan van Hoof. Desuden blev Mon...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch